Market Research Logo

Potential "Pipeline Disruptors" - New Products That Will Drive The Future Pharmaceutical Market

  • Executive Summary
    • Introduction
    • What are Pipeline Disruptors?
      • Gilead Sciences Disrupts HCV Market
        • Table Figure 1-1: Gilead Sciences Dominates HCV Market, Displaces Current Therapies ($ millions)
      • Bristol-Myers Squibb - Opdivo Disrupts Monoclonal Antibody Performance in Cancer
        • Table Figure 1-2: Monoclonal Antibodies in Cancer Treatment, Opdivo Performance vs. Industry, 2010-2022
    • Scope and Methodology
    • Market Outlook
      • Table Figure 1-3: Projected Opportunities in Six Major Biopharmaceutical Specialties, 2010-2022
  • The Status of the Global Biopharmaceutical Market
    • Target Selection Process Increases in Importance
    • Top R&D Spenders
      • Table Top R&D Spenders in the Pharmaceutical Industry - 2014-2016, (millions of $) R&D Spending 2014 2015 2016 CAGR 2014-2016
      • Table Figure 2-1: Top R&D Spenders in the Pharmaceutical Industry, 2016 ($ millions)
    • Major Segment Breakthroughs
      • Monoclonal Antibodies (mAbs)
        • Table Figure 2-2: Monoclonal Antibody Market Penetration, All Indications (percent of total biopharmaceutical market)
      • Kinase Inhibitors
        • Table Figure 2-3: Tyrosine Kinase Inhibitor Market Penetration, All Indications (percent of total biopharmaceutical market)
    • Industry Trends
      • Healthcare Spending
        • Table Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015
    • Global Demographics and the Need for Effective Therapies
      • Table Global Population will Increase to Nearly 9.4 billion by 2050 (population in millions) 1980-2050
      • Table Figure 2-4: The Global Population, 1980-2050 (in millions)
      • Aging Population
        • Table Figure 2-5: Global Population Trend, Age 65+ (thousands)
  • Company Innovation Strategies
    • Strategies: The Path to Pipeline Disruptor Innovation
      • AbbVie's Growth Strategy
      • Allergan's Growth Strategy
      • Astellas' Growth Strategy
      • AstraZeneca's Growth Strategy
      • Bayer's Growth Strategy
      • Boehringer Ingelheim's Growth Strategy
      • Bristol-Myers Squibb's Growth Strategy
      • Celgene's Growth Strategy
      • Eli Lilly & Company's Growth Strategy
      • Gilead Sciences' Growth Strategy
      • GlaxoSmithKline's Growth Strategy
      • Johnson & Johnson's Growth Strategy
      • Novartis' Growth Strategy
      • Pfizer's Growth Strategy
      • Roche's Growth Strategy
      • Teva Pharmaceuticals' Growth Strategy
  • Pipeline Disruptors: Alzheimer's Disease
    • Market Opportunity
      • Table Figure 4-1: Global Incidence and Prevalence of Alzheimer's Disease by Country, 2016 estimates
    • Treatment Options in Alzheimer's Disease: Current Market Landscape
      • Aricept (donepezil)
      • Exelon (rivastigmine)
      • Namenda/Namzaric (memantine)
      • Razadyne (galantamine)
        • Table Figure 4-2: Alzheimer's Disease Market by Drug Type ($ millions)
    • Innovation Pipeline
      • Table AstraZeneca/Eli Lilly - Lanabecestat (AZD3293/LY3314814)
      • Table Biogen/Neurimmune – Aducanumab
      • Table Biogen/Eisai - E2609
      • Table Roche - RG1450 (gantenerumab)
      • Table Roche - RG7412 (crenezumab)
      • Table Takeda - AD-4833/TOMM40 Name Pioglitazone
    • Market Impact Forecast
      • Table Figure 4-3: Monoclonal Antibodies and BACE Inhibitors will Drive Alzheimer's Disease Treatment Growth, 2016-2022 ($ millions)
      • Table Figure 4-4: Roche and Biogen Expected to Dominate Alzheimer's Treatment Market in 2022 (% market share)
  • Pipeline Disruptors: Asthma
    • Market Opportunity
      • Table Figure 5-1: China and U.S. at Top of List for Asthma Prevalence, 2016 estimates
    • The Heavy Hitters in Asthma Treatment: Current Market Landscape
      • Pulmicort (budesonide)
      • Seretide/Advair (fluticasone/salmeterol)
      • Spiriva (tiotropium bromide)
      • Symbicort (budesonide/formoterol)
      • Ventolin (albuterol)
      • Xolair (omalizumab)
        • Table Leading Asthma Product Sales (Global), 2016 ($ in millions)
        • Table Figure 5-2: Asthma Market Shows Corticosteroids Treatment of Choice, Sales by Drug Type 2010-2016 ($ millions)
    • Innovation Pipeline
      • Table AstraZeneca – Tralokinumab
      • Table AstraZeneca – Benralizumab
      • Table Novartis - QVM149
      • Table Novartis – Fevipiprant
      • Table Novartis - QMF149
    • Market Impact Forecast
      • Table Figure 5-3: Combination Treatments Expected to Revive Asthma Treatment Market, Product Growth by Segment 2016-2022 ($ millions)
      • Table Figure 5-4: Novartis will Surge Ahead in Asthma Treatment Market by 2022 (% market share)
  • Pipeline Disruptors: Breast Cancer
    • Market Opportunity
      • Table Most Common Cancer by Incidence, by Region and Gender Region Males Females First Second First Second
      • Table Figure 6-1-: Global Incidence and Mortality of Breast Cancer by Country, 2012*
    • The Heavy Hitters in Breast Cancer Treatment: Current Market Landscape
      • Abraxane (paclitaxel)
      • Afinitor (everolimus)
      • Avastin (bevacizumab)
      • Herceptin (trastuzumab)
      • Ibrance (palbociclib)
      • Perjeta (pertuzumab)
        • Table Leading Breast Cancer Product Sales (Global), 2016 ($ in millions)
        • Table Figure 6-2: Breast Cancer Market Driven by Monoclonal Antibodies, Market by Drug Type 2010-2016 ($ millions)
    • Innovation Pipeline
      • Table Novartis – Alpelisib
      • Table Novartis - Kisqali (ribociclib)
      • Table Pfizer – Trastuzumab
      • Table Roche - Taselisib
    • Market Impact Forecast
      • Table Figure 6-3: 2 Leading Product Segments in Breast Cancer Treatment, 2016-2022 ($ millions)
      • Table Figure 6-4: A New Market Leader Will Emerge in 2022 (% market share)
  • Pipeline Disruptors: Leukemia
    • Market Opportunity
      • Table Leukemia Overview by Type
      • Table Figure 7-1: Distribution of Leukemia Cases by Type
      • Table Figure 7-2: Global Incidence and Mortality of Leukemia by Country, 2012*
    • The Heavy Hitters in Leukemia Treatment: Current Market Landscape
      • Gleevec/Glivec (imatinib)
      • Imbruvica (ibrutinib)
      • Rituxan/MabThera (rituximab)
      • Sprycel (dasatinib)
      • Tasigna (nilotinib)
        • Table Leading Leukemia Product Sales (Global), 2016 ($ in millions)
        • Table Figure 7-3: Leukemia Market Driven by Tyrosine Kinase Inhibitors, Market for Leukemia Treatment by Drug Type, 2010-2016 ($ millions)
    • Innovation Pipeline
      • Table AstraZeneca – Acalabrutinib
      • Table Celgene – Enasidenib
      • Table Daiichi Sankyo – Quizartinib
      • Table Novartis - CTL019
      • Table Novartis - GP2013 (rituximab)
      • Table Novartis – Midostaurin
      • Table Pfizer - Besponsa (inotuzumab ozogamicin)
      • Table Roche - RG7388 (idasanutlin)
    • Market Impact Forecast
      • Table Figure 7-4: Leukemia Treatment Product Growth ($ millions)
      • Table Figure 7-5: Novartis will Maintain Leading Position in Leukemia Treatment Market Through 2022 (% market share)
  • Pipeline Disruptors: Lung Cancer
    • Market Opportunity
      • Table Types of Primary Lung Cancer
      • Table Most Common Cancer by Incidence, by Region and Gender Region Males Females First Second First Second
      • Table Figure 8-1: Global Incidence and Mortality of Lung Cancer by Country, 2012*
    • The Heavy Hitters in Lung Cancer Treatment: Current Market Landscape
      • Abraxane (paclitaxel)
      • Alimta (pemetrexed)
      • Avastin (bevacizumab)
      • Opdivo (nivolumab)
      • Tarceva (erlotinib)
        • Table Leading Lung Cancer Product Sales (Global), 2016 ($ in millions)
        • Table Figure 8-2: Lung Cancer Market by Drug Type ($ millions)
    • Innovation Pipeline
      • Table Boehringer Ingelheim - BI 695502
      • Table Novartis - INC280
      • Table Pfizer - PF-06439535
      • Table Roche – Alecansa
    • Market Impact Forecast
      • Table Figure 8-3: Lung Cancer Treatment Product Growth, 2016-2022 ($ millions)
      • Table Figure 8-4: Eli Lilly Slips, Who Gains in 2022? (% market share)
  • Pipeline Disruptors: Lymphoma
    • Market Opportunity
      • Non-Hodgkin's Lymphoma
        • Table Classification of Non-Hodgkin's Lymphomas
      • Hodgkin's Lymphoma
        • Table Figure 9-1: Global Incidence and Mortality of Lymphoma by Country, 2012*
    • The Heavy Hitters in Lymphoma Treatment: Current Market Landscape
      • Alimta (pemetrexed)
      • Imbruvica (ibrutinib)
      • Opdivo (nivolumab)
      • Revlimid (lenalidomide)
      • Rituxan/MabThera (rituximab)
      • Velcade (bortezomib)
        • Table Leading Lymphoma Product Sales (Global), 2016 ($ in millions)
        • Table Figure 9-2: Lymphoma Market by Drug Type ($ millions)
    • Innovation Pipeline
      • Table Bayer – Copanlisib
      • Table Novartis - CP2013 (rituximab)
      • Table Pfizer - PF-05280586
    • Market Impact Forecast
      • Table Figure 9-3: Lymphoma Treatment Product Growth, 2016-2022 ($ millions)
      • Table Figure 9-4: Bayer's Lymphoma Candidate and Potential in the Market (% market share)
  • Market Conclusions
    • Age-Driven Growth - Feeling the True Impact
    • Key Chronic Diseases That Will Affect Markets
    • Watch Combination Therapies
    • Outcomes-Based Reimbursement Changes Game
    • Disease-Modifying Therapies for Alzheimer's Disease
    • The Cost of Developing New Targets is Increasing and the Risk of Failed Development is a Real Threat to New Innovation
    • Biosimilar Development Will Cut into Sales for Original Therapies

Potential Pipeline Disruptors: Innovative Pharmaceuticals in Alzheimer's Disease, Asthma and Cancer

This report covers market opportunities based on pipeline developments for six key therapeutic specialities:

  • Alzheimer's Disease
  • Asthma
  • Breast Cancer
  • Leukemia
  • Lung Cancer
  • Lymphoma
These six areas are expected to show the strongest pipeline impact and candidates are likely to replace current therapies. The market is evaluated for 2015 and 2016 with forecast data provided through 2022. Forecast data were derived from a combination of pipeline analyses, current product treatment guidelines, potential candidate clinical trial results and other factors that may affect the performance of either current or future sales of a particular therapy. Although a thorough analysis and best effort has been made to provide a reliable market forecast, changes can occur which would affect company sales forecasts, market positions/shares, and overall market values. These may include a high-profile merger, a promising late development project deemed not approvable, an unforeseen patent extension of a high-sale therapy, a major production or manufacturing setback, or any other similarly unpredictable event.


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;